Scapula

Exactech AI Platform Surpasses 100,000 Joint Replacement Surgeries Worldwide

Retrieved on: 
Monday, November 20, 2023

Exactech , a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today its Active Intelligence® (AI) platform surpassed more than 100,000 total joint replacement surgeries across the globe.

Key Points: 
  • Exactech , a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today its Active Intelligence® (AI) platform surpassed more than 100,000 total joint replacement surgeries across the globe.
  • View the full release here: https://www.businesswire.com/news/home/20231120575358/en/
    Exactech Active Intelligence® (AI) empowers surgeons with data-rich, low-cost solutions that help improve patient outcomes.
  • “As a leader in orthopaedic innovations, Exactech is focused on pushing technological boundaries to deliver a best-in-class platform of enabling technologies and smart solutions.
  • ExactechGPS, Equinoxe Planning App and Predict+ are developed by Blue Ortho, an Exactech subsidiary, and distributed by Exactech, Inc.

Emory Healthcare Researcher Wins Two Awards Using Konica Minolta’s AI Analysis Tool With Dynamic Digital Radiography in Shoulder Pathology

Retrieved on: 
Friday, October 14, 2022

Dr. Hussains research evaluated a prototype artificial intelligence (AI) tool developed by Konica Minolta Healthcare for characterizing shoulder dynamics.

Key Points: 
  • Dr. Hussains research evaluated a prototype artificial intelligence (AI) tool developed by Konica Minolta Healthcare for characterizing shoulder dynamics.
  • Seventy-three shoulders (23 normal controls, 41 rotator cuff tears and nine adhesive capsulitis) were imaged using Dynamic Digital Radiography (DDR) and reviewed by two trained readers.
  • With the DDR image data, Dr. Hussain was able to visualize changes in shoulder pathology and, using the proof-of-concept AI tool, acquire measurements to calculate the scapulohumeral rhythm (SHR).
  • The new AI tool employs a machine learning algorithm utilizing a convolutional neural network architecture to automate this analysis.

Epic Bio Presents Proprietary Gene Expression Modulation System (GEMS) Demonstrating Precise Engineering of DUX4 Gene in Facioscapulohumeral Muscular Dystrophy

Retrieved on: 
Thursday, October 13, 2022

I am excited by the data we will present today on Facioscapulohumeral Muscular Dystrophy (FSHD), the second most prevalent form of muscular dystrophy.

Key Points: 
  • I am excited by the data we will present today on Facioscapulohumeral Muscular Dystrophy (FSHD), the second most prevalent form of muscular dystrophy.
  • Notably, our in vitro results demonstrate the utility of our dCas to suppress DUX4 expression by up to 95%.
  • Facioscapulohumeral Muscular Dystrophy is estimated to be the second most common muscular dystrophy, affecting 1 in 8,000 patients1,2.
  • The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies.

Exactech Launches Significant Update to Equinoxe® Shoulder Preoperative Planning App

Retrieved on: 
Monday, July 18, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220718005241/en/
    Exactech Launches Significant Update to Equinoxe Shoulder Preoperative Planning App (Photo: Business Wire)
    The shoulder preoperative planning software can be used with the ExactechGPS navigation system in the operating room, connecting the preoperative plan with implant placement.
  • Since the launch of the original Equinoxe Planning App, surgeons have planned more than 50,000 shoulder cases and executed their plans in 30,000+ cases using GPS, said Exactech Senior Vice President of Extremities Chris Roche.
  • The Equinoxe Planning App is used exclusively with the Equinoxe Platform Shoulder System and its comprehensive glenoid and humeral solutions.
  • ExactechGPS and the Equinoxe Planning App are manufactured by Blue Ortho, a subsidiary of Exactech, and distributed by Exactech.

Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

Retrieved on: 
Tuesday, July 5, 2022

CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the first patient has been dosed in REACH, a Phase 3 clinical trial designed to evaluate the safety and efficacy of losmapimod for the treatment of FSHD. The randomized, double-blind, placebo-controlled, multi-national Phase 3 trial will enroll approximately 230 adults at over 30 sites in North America and Europe. The pivotal trial is designed to support the U.S. FDA and European Medicines Agency (EMA) regulatory applications of lospmapimod for the treatment of FSHD. If approved, losmapimod would be the first and only therapy for the disease.

Key Points: 
  • The randomized, double-blind, placebo-controlled, multi-national Phase 3 trial will enroll approximately 230 adults at over 30 sites in North America and Europe.
  • The pivotal trial is designed to support the U.S. FDA and European Medicines Agency (EMA) regulatory applications of lospmapimod for the treatment of FSHD.
  • Results from Fulcrums Phase 2 clinical trial, ReDUX4, demonstrated that losmapimod was superior to placebo across a number of clinically relevant endpoints.
  • However, while Fulcrum may elect to update these forward-looking statements at some point in the future, Fulcrum specifically disclaims any obligation to do so.

Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting

Retrieved on: 
Friday, April 1, 2022

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple oral and poster presentations on losmapimod for facioscapulohumeral muscular dystrophy (FSHD) at the American Academy of Neurology’s Annual Meeting, taking place April 2-7 in Seattle, WA. These presentations highlight clinical data supporting the potential of losmapimod as well as the design of the Phase 3 REACH trial of losmapimod in FSHD.

Key Points: 
  • These presentations highlight clinical data supporting the potential of losmapimod as well as the design of the Phase 3 REACH trial of losmapimod in FSHD.
  • FSHD is a progressive, relentless, and debilitating disease for which there are no approved therapies, said Christopher Morabito, MD, Fulcrums chief medical officer.
  • The presentations will also be available for viewing to registered conference attendees during the virtual AAN 2022 Annual Meeting taking place April 24-26.
  • However, while Fulcrum may elect to update these forward-looking statements at some point in the future, Fulcrum specifically disclaims any obligation to do so.

Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

Retrieved on: 
Thursday, March 17, 2022

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will host a Key Opinion Leader (KOL) meeting on Thursday, March 24, 2022 from 10:00am – 12:00pm ET to discuss the company’s program with losmapimod for facioscapulohumeral muscular dystrophy (FSHD).

Key Points: 
  • To register for the live webcast please visit https://ir.fulcrumtx.com/events-and-presentations in the Investor Relations section of the companys website.
  • Following the live webcast, an archived replay will be available on the website for up to 12 months.
  • It is characterized by fat infiltration of skeletal muscle leading to muscular atrophy involving primarily the face, scapula and shoulders, upper arms, and abdomen.
  • However, while Fulcrum may elect to update these forward-looking statements at some point in the future, Fulcrum specifically disclaims any obligation to do so.

Exactech Smart Shoulder Technology Now Features Humeral Planning and Joint Motion

Retrieved on: 
Wednesday, February 2, 2022

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announces 510(k) clearance of the Equinoxe Planning App (v. 2.0).

Key Points: 
  • Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announces 510(k) clearance of the Equinoxe Planning App (v. 2.0).
  • View the full release here: https://www.businesswire.com/news/home/20220202005829/en/
    The Equinoxe Planning App (v.2.0) allows for humeral head offsets and replicator plate positioning.
  • The Equinoxe Planning App is used exclusively with the Equinoxe Platform Shoulder System and its comprehensive glenoid solutions.
  • ExactechGPS and the Equinoxe Planning App are manufactured by Blue Ortho, a subsidiary of Exactech, and distributed by Exactech.

Globus Medical Premieres ANTHEM® Mini Fragment Fracture System at Orthopaedic Trauma Association Meeting

Retrieved on: 
Tuesday, October 19, 2021

AUDUBON, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced it will feature its new ANTHEM Mini Fragment Fracture System at the annual Orthopaedic Trauma Association (OTA) meeting in Fort Worth, Texas, Oct 20-23, 2021.

Key Points: 
  • AUDUBON, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced it will feature its new ANTHEM Mini Fragment Fracture System at the annual Orthopaedic Trauma Association (OTA) meeting in Fort Worth, Texas, Oct 20-23, 2021.
  • The ANTHEM Mini Fragment Fracture System is designed for fracture fixation of small bones and non-load-bearing stabilization of long bones in the upper and lower extremities.
  • With ANTHEM Mini Fragment, surgeons now have an adaptable small plating system designed to better fit the challenging anatomy encountered in these procedures.
  • Surgeons wanting to experience ANTHEM Mini Fragment Fracture Systems benefits firsthand shouldvisit Globus Medical booth #509 at this weeks OTA meeting.

Tyber Medical Receives Largest FDA 510(k) Clearance For Expanded Line Of Anatomical Plating Systems

Retrieved on: 
Wednesday, September 1, 2021

BETHLEHEM, Pa., Sept. 1, 2021 /PRNewswire/ --Tyber Medical, LLC, a leading orthopedic device manufacturer providing private label orthopedic implants for the trauma, extremity, and spine markets, received its second and largest U.S. Food and Drug Administration (FDA) 510(k) clearance for its expanded line of anatomical plating systems.

Key Points: 
  • BETHLEHEM, Pa., Sept. 1, 2021 /PRNewswire/ --Tyber Medical, LLC, a leading orthopedic device manufacturer providing private label orthopedic implants for the trauma, extremity, and spine markets, received its second and largest U.S. Food and Drug Administration (FDA) 510(k) clearance for its expanded line of anatomical plating systems.
  • With more than 1,500 SKUs included in the clearance, Tyber Medical now offers its most comprehensive portfolio of fixation devices for the extremities.
  • Tyber Medical's largest FDA Clearance makes it a complete source for orthopedic plating for the private label market.
  • "Our second and largest FDA Clearance makes Tyber Medical a complete source for orthopedic plating for our partners and the surgeons they serve," said Tyber Medical CEO Jeff Tyber.